Healthcare Industry News: sanofi-aventis
News Release - April 12, 2006
Mylan Announces Tentative Approval for Fexofenadine Hydrochloride TabletsPITTSBURGH, April 12 (HSMN NewsFeed) -- Mylan Laboratories Inc. (NYSE: MYL ) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application (ANDA) for Fexofenadine Hydrochloride Tablets, 30mg, 60mg and 180mg. Fexofenadine Hydrochloride Tablets are the AB-rated generic equivalent of Aventis Pharmaceuticals' AllegraŽ Tablets, which had annual U.S. sales of approximately $1.4 billion as of December 31, 2005, according to IMS Health
About Mylan Laboratories
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc. that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.
For more information about Mylan, visit http://www.mylan.com.
Source: Mylan Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.